Business
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining the World Health Organization’s (WHO) 2022 World Mental Health Day campaign to make mental health and well-being for all a global priority. According to the WHO’s World Mental Health Report, approximately one billion people are living with a mental disorder and nearly three hundred million adults have depression worldwide [1,2]. The ubiquity of mental health disorders results in an estimated 12 billion workdays lost annually due to depression and anxiety alone, and results in costs to the global economy of nearly one trillion dollars [3]. “Axsome shares the World Health Organization’s vision of a world in which mental health is valued, promoted and protected. We are pleased to add our voice to raise awareness of mental health on this important day,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Given the growing prevalence of depression and other mental health conditions, the need for effective new treatments that are accessible to all has never been greater. We are committed to doing our part to discover, develop and deliver new medicines to the millions of individuals living with mental health conditions in the U.S. and around the globe.” A variety of mental well-being resources from the World Health Organization are available at https://www.who.int/news-room/feature-stories/mental-well-being-resources-for-the-public. As part of Axsome’s commitment to depression education, resources and tools are available at www.talkdepressettling.com to help support those affected by depression. About Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate mat...